Company / Debt per Share
Xeris Biopharma Holdings, Inc. Debt per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Debt per Share
$1.47
FY2025
5-year range
$1.40 / $2.07
FY2021-FY2025
Trend
-12.2%
vs FY2024
Sector context
#50 of 82
Health Care
What the data says
At $1.47, Xeris Biopharma Holdings, Inc.'s debt per share ranks #33 of 82 in the Health Care sector. Debt per Share has fluctuated over the past 6 years, ranging from $1.40 in FY2023 to $2.07 in FY2021.
Based on SEC 10-K filings.
1.47 in FY2025 with a 5-year CAGR of -6.3%.
Increased from $1.40 to $1.47 over the past 2 years.
Health Care sector context is included.
Debt per Share over time
Growth rates
- 3-Year CAGR
- -0.5%
- 5-Year CAGR
- -6.3%
- 10-Year CAGR
- -
Sector benchmark
#33 of 82 in Health CareTop 39% of 82This company $1.47 Sector average $151.59
▼
-99.0% below sector average
Key checks
Key Insights
- In FY2025, debt per share decreased 12.2% year-over-year.
- Ranks #50 out of 82 companies in the Health Care sector.
- Peak debt per share was recorded in FY2021.
- Lowest debt per share in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.47 | -12.2% |
| FY2024 | $1.68 | +19.9% |
| FY2023 | $1.40 | -6.5% |
| FY2022 | $1.50 | -27.5% |
| FY2021 | $2.07 | +1.2% |
| FY2020 | $2.04 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026